

Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time

Benjamin Davido, Ghilas Boussaid, Isabelle Vaugier, Thibaud Lansaman, Frédérique Bouchand, Christine Lawrence, Jean-Claude Alvarez, Pierre Moine, Véronique Perronne, Frédéric Barbot, et al.

▶ To cite this version:

Benjamin Davido, Ghilas Boussaid, Isabelle Vaugier, Thibaud Lansaman, Frédérique Bouchand, et al.. Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time. International Journal of Antimicrobial Agents, 2020, 56 (4), pp.106129. 10.1016/j.ijantimicag.2020.106129. hal-02976748

HAL Id: hal-02976748 https://hal.uvsq.fr/hal-02976748

Submitted on 21 Sep 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés. Version of Record: https://www.sciencedirect.com/science/article/pii/S0924857920303125 Manuscript_91195136324562fe844d169373551be2

1 Impact of medical care including anti-infective agents use on the prognosis of

2 COVID-19 hospitalized patients over time

- 3 Benjamin Davido¹, Ghilas Boussaid², Isabelle Vaugier³, Thibaud Lansaman⁴,
- 4 Frédérique Bouchand⁵, Christine Lawrence⁶, Jean-Claude Alvarez⁷, Pierre Moine⁸,
- 5 Véronique Perronne¹, Frédéric Barbot³, Azzam Saleh-Mghir¹, Christian Perronne¹,
- 6 Djillali Annane⁸, Pierre De Truchis¹, on behalf of the COVID-19 RPC Team*
- ⁷ ¹ Maladies Infectieuses, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré,
- 8 Garches, France
- ⁹ ² Université Paris-Saclay, UVSQ, Erphan, 78000, Versailles, France.

³ Centre d'Investigation Clinique (Inserm CIC 1429), Université Paris-Saclay, AP-HP

11 Hôpital Raymond Poincaré, Garches, France

⁴ Rééducation fonctionnelle, Université Paris-Saclay, AP-HP Hôpital Raymond
 Poincaré, Garches, France

⁵ Pharmacie Hospitalière, Université Paris-Saclay, AP-HP Hôpital Raymond
 Poincaré, Garches, France

⁶ EOH, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré, Garches, France

- ¹⁷ ⁷ Pharmaco-toxicologie, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré,
- 18 Garches, France
- ¹⁹ ⁸ Réanimation médicale, Université Paris-Saclay, AP-HP Hôpital Raymond Poincaré,
- 20 Garches, France

21

22 Keywords: azithromycin, hydroxychloroquine, Covid-19, pneumonia

23	
24	
25	
26	
27	Corresponding author:
28	Benjamin Davido, Service de Maladies Infectieuses et Tropicales
29	Hôpital Raymond-Poincaré, Garches 92380, France.
30	Tel: +33-1-47107758, e-mail: benjamin.davido@aphp.fr
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	Abstract:
41	Introduction: Interest of anti-infective agents in COVD-19 showed discrepant results.
42	However, there is no evaluation about the impact in changes of practices on the
43	prognosis over time.
44	Methods: Single center, retrospective study, conducted from March 5th to April 25th
45	2020, in adults hospitalized in a medicine ward for a COVID-19. Patient
46	characteristics were compared between 2 periods (before/after March 19th)

47 considering French guidelines issued by learned societies. Aim of the study was to

evaluate how medical care impacted unfavorable outcome, namely admission in
intensive care unit (ICU) and/or death.

Results: One hundred thirty-two patients were admitted, mean age was 59.0 ± 16.3 50 years, mean CRP level was 84.0±71.1 mg/L, 46% had a lymphocyte 51 count<1000/mm³. When prescribed, anti-infective agents were lopinavir-ritonavir 52 (n=12), azithromycin (AZI) (n=28) and AZI combined with hydroxychloroquine (HCQ) 53 (n=52). Between the 2 periods we noted a significant decrease of ICU admission, 54 from 43% to 12% (p<0.0001). Delays until transfer in ICU were similar between 55 periods (p=0.86). Pulmonary CT-scan were significantly more performed (from 50%) 56 to 90%, p<0.0001), as oxygen-dependency (53% vs 80%, p=0.001) and prescription 57 of AZI±HCQ (from 25% to 76%, p<0.0001) were greater over time. Multivariate 58 analyses showed a reduction of unfavorable outcome in patients receiving AZI±HCQ 59 (HR=0.45, 95%IC [0.21-0.97], p=0.04), especially among an identified category of 60 individuals (lymphocyte≥1000/mm³ or CRP≥100 mg/L). 61

62 <u>Conclusion:</u> The present study revealed a significant decrease of admission in ICU 63 over time probably related to multiple factors, including a better indication of 64 pulmonary CT-scan, of oxygen therapy, and a suitable prescription of anti-infective 65 agents.

66

67 Introduction:

68 Management and medical care of COVID-19 pneumonia in hospitalized patients is 69 currently still debated, especially because data regarding an emerging pathogen are

constantly evolving over time and across countries. Numerous therapies including
oxygen, anti-infective agents and corticosteroids have been proposed.

Historically, Gautret et al. [1,2] and Million et al. [3] observed in Marseille (France) 72 that a combination therapy using hydroxychloroguine (HCQ) and azithromycin (AZI) 73 could potentially reduce viral shedding and the incidence of COVID-19 pneumonia. 74 Concomitantly, an observational study conducted by Mahevas et al. [4] evaluating 75 HCQ alone prescribed in an in-hospital setting, showed no impact of HCQ on the 76 transfer rate in intensive care unit (ICU) and/or death. This study is concordant with a 77 publication issued in the United States by Geleris et al. [5] who concluded that HCQ 78 administration was not associated with a greatly lowered risk of intubation or death. 79

Interestingly, although corticosteroids were considered potentially harmful in the early 80 care of COVID-19 infected patients [6], the RECOVERY trial (NCT04381936) stated 81 that dexamethasone could reduce mortality rate up to 30% in severely-ill patients 82 admitted for a COVID-19 pneumonia and revealed no interest of HCQ (data not 83 published), meanwhile the azithromycin arm is still being investigated. Very recently a 84 multicenter study in the United States reopened the debate concerning the efficacy of 85 HCQ with or without AZI [7]. Furthermore antiviral therapies, notably lopinavir-86 ritonavir, revealed no benefit in comparison to standard of care in a large 87 randomized trial [8], whereas remdesivir showed a reduction in time to clinical 88 improvement in 2 trials but no significant impact on mortality [9,10]. 89

Overall those reports have raised concerns about the true interest of anti-infective agents in COVID-19 pneumonia in a context where medical practices between these different studies are heterogeneous and have evolved over time. Indeed, in the

absence of a clear recommendation for treatment initiation, it is difficult to assume or
to invalidate the effect of anti-infective agents on the prognosis of COVID-19 patients.

To our knowledge, there is no evaluation over time about changes of practices, including anti-infective agents, and their impact on the prognosis of patients admitted in a medical ward for a COVID-19 pneumonia. Considering controversies, we retrospectively evaluated the potential factors associated with an unfavorable outcome, namely admission in ICU and/or death, during this first wave of the epidemic.

101

102 Methods:

103 Setting

We conducted a single center and retrospective study, from March 5th to April 25th
2020, regarding adults admitted in our medicine wards in a tertiary university hospital
namely Hôpital Raymond Poincaré (AP-HP), Garches, France.

We included all the adults admitted in medicine for a COVID-19 infection confirmed by SARS-CoV-2 RT-PCR and/or a compatible pulmonary CT-scan. Exclusion criteria were: i) patients directly admitted in ICU; ii) patients discharged from ICU to a medicine ward; iii) opposition to collect data expressed by the patient.

111

112 Data collection

113 The following data were collected from patient's medical charts:

Patient characteristics: age, sex, diabetes, cardiovascular risk factors, smoking
 habits, obesity, chronic pulmonary disease, Charlson comorbidity index (CCI) [11],

Infection characteristics: delay between onset of symptoms and admission,
 presence of super-infection, C-reactive protein (CRP) and white blood cell count
 (WBC) at admission, percentage of lung injuries on CT-scan if applicable, positive
 PCR amplifying the betacoronavirus E gene and the SARS-CoV-2 RdRp gene on
 nasopharyngeal swab or sputum,

Treatment characteristics: requiring ICU support with invasive ventilation and
 associated therapeutic strategies (e.g. oxygen, anti-infective agents),

Endpoint was defined as unfavorable outcome assessed by the requirement of a
 transfer in ICU for invasive ventilation and/or death within 30 days,

Patients were followed-up until hospital discharge. After discharged, patients were
monitored during 30 days by the telemedicine through the French covidom platform
[12],

Derived variables: moderate lymphocytopenia was based on a lymphocyte count
 with a threshold at 1000/mm³ and high systemic inflammation was defined as a CRP
 threshold ≥ 100 mg/L.

131

132 Treatment strategies

All patients who required oxygen received systematically a beta-lactam for at least 5 days, using preferentially ceftriaxone or cefotaxime to treat a potential superinfection.

Patients were eligible to a supposed effective anti-infective agent against COVID-19 (HCQ, AZI, lopinavir-ritonavir), independently of biological abnormalities and considering the following indications: i) patient presenting a clinical pneumonia confirmed by SARS-CoV-2 PCR, requiring oxygen therapy (independently of the CT scan findings); ii) high suspicion of COVID-19 pneumonia considering the clinical presentation and/or pulmonary CT-scan showing ground-glass opacity affecting \geq 10% of the whole parenchyma.

Patients were categorized as receiving an anti-infective agent once they received at least one dose. Patients who received lopinavir-ritonavir were categorized in no treatment group, considering this antiviral drug did not show any benefit for the treatment of COVID-19 [7].

147 Before HCQ or AZI initiation, patients had systematically an electrocardiogram (ECG) to evaluate the corrected QT interval using the Framingham formula, and monitored 2 148 times per week during the whole treatment, as well as serum potassium levels. A 149 loading dose at day 1 with 800 mg/day was administered followed by a maintenance 150 dose of 400 mg/day up to 600 mg/day in case of obesity (body mass index (BMI) > 151 30) for a total 10 days. In addition, 500 mg of azithromycin was prescribed the first 152 day, followed by 250 mg for 4 days. Patients were informed that HCQ and lopinavir-153 ritonavir were currently off-label for the treatment of COVID-19 pneumonia until the 154 25th of March 2020 in France, where the ministerial decree #2020-314 authorized the 155 in-hospital prescription of HCQ in this particular indication. In case they refused the 156 prescription of HCQ or the latter was contraindicated (by ECG or drug interactions), it 157 158 was noted into their medical chart and patients did not receive HCQ.

159

160 *Objective*

Aim of the study was to describe the medical care over time (oxygen therapy, antiinfective agents, pulmonary CT-scan) and to determine whether potential factors were related to an unfavorable outcome (transfer in ICU and/or death).

164

165 Statistical analysis

Descriptive statistics are presented as counts and percentages, or means and standard deviations, with skewed continuous data summarized as medians and interquartile ranges.

Two periods have been defined, the first two weeks (March 5th to March 19th) and 169 thereafter where practices have become more standardized (March 20th to April 25th) 170 considering the French COVID-19's guidelines issued by learned societies 171 concerning the management of patients in ICU [13]. Patients were grouped according 172 to these two periods, and compared. A Student test (equal variance) or Welche 173 Satterthwaite t-test (unequal variance) was used to analyze quantitative variables, a 174 Mantel-Haenszel Chi-Square test was used to analyze gualitative variables and 175 Fisher's exact test was used when the sample sizes were small (n<5). 176

177 Moving averages over 15 days have been plotted to describe the evolution of care 178 management over time using the following formula:

179
$$\bar{x}_n = \frac{1}{15} \sum_{k=-7}^{k=+7} x_{n-k}$$

180 Time to endpoint was calculated from the date of hospitalization to the date of 181 unfavorable outcome or hospital discharge. Two Cox proportional-hazards models

were used to estimate hazard ratios (HR) for unfavorable outcome associated with medical care, after adjustment on risk factors and one biological parameter (one included the lymphocyte count and the other one included the CRP level). Potential factors included were CCI (including age), obesity, oxygen flow and treatment. Interactions between treatment and lymphocyte count or CRP level were tested and Kaplan-Meier curves were plotted to assess unfavorable outcome from admission depending on these biological parameters.

Statistical significance was set at 0.05 (two-tailed test). All statistical calculations
were performed using R software version 4.2.0.

191

192 Compliance with Ethical Standards

All procedures performed in studies involving human participants were in accordance with the ethical standards and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study has passed the CESREES/Health Data Hub regarding ethics committee approval (MR1811190620) and is registered on ClinicalTrials.gov (NCT04453501). As part of an anonymous and retrospective study, a non-opposition and information letter was sent to participants afterwards.

200

201 **Results:**

202 **Description of the population**

Between March 5th and April 25th 2020, 132 patients with Covid-19 were hospitalized.
At baseline, mean age was 59.0 ± 16.3 years with 64% male. Among them, 11%

were obese (BMI>30), 22% were smokers, 23% had a CCI > 5 and 46% had a lymphocyte count <1000/mm³. Mean CRP level was 84.0 \pm 71.1 mg/L with 46% greater than 100 mg/L. Seventy-two percent of patients were oxygen-dependent at admission, with 8% of patients with an oxygen flow therapy greater than 5 L/min. Among the patients who underwent a pulmonary CT scan, 83% had lung injuries compatible with COVID-19 greater than 10% of the whole parenchyma. SARS-CoV-2 RT-PCR was positive in 95.5% (n=126) of cases.

212

213 **Treatment strategies**

Overall, 92 (70%) patients received one anti-infective agent. Among them, 12 (13%) received lopinavir-ritonavir, 28 (29%) azithromycin (AZI) and 52 (55%) AZI combined with HCQ (**Table S1 in Supplementary Data**). Mean delay from admission to treatment initiation was 0.7 +/- 1.5 days. Moreover, delay before treatment initiation was similar between first and second period (1.3 +/- 1.9 days vs 0.8 +/- 1.1 days, p=0.46). Of note, only one patient in the no treatment group received after 14 days of hospitalization a short course of oral corticosteroids.

During the first period, 40 (30%) patients were hospitalized whereas 92 (70%) were 221 admitted thereafter. There were significantly more oxygen-dependent patients 222 hospitalized during the second period than the first one (80% vs 53%, p=0.001). Also, 223 a significant higher number of pulmonary CT scan performed was observed over time 224 between periods of hospitalization from 50% to 90% (p<0.0001), independently of 225 CT-scan severity (Table 1). Concomitantly, prescription of AZI whether or not 226 combined with HCQ increased over time, from 25% to 76% between the 2 periods 227 (p<0.0001) (Figure 1). 228

Of note, among patients who did not receive HCQ, 5 had cardiac contraindication and 2 refused to be treated with this molecule. During the course of treatment using AZI in combination with HCQ, we report only 1 patient that presented an adverse event (a prolonged QT interval on ECG without clinical event) that led to discontinuation of HCQ within 48h, and was switched to azithromycin alone.

234

235 Unfavorable outcome (ICU admission or death)

A total of 28 (21%) patients had an unfavorable outcome, among them 26 (93%) were transferred to ICU and 2 (7%) died without being transferred in ICU. Mean delay between hospitalization and admission in ICU was 2.45 ± 1.45 days (2.4 ± 1.5 days during the first period vs 2.4 ± 1.6 days during the second one, p=0.86). A trend towards a lower frequency of admission to ICU was observed, from 43% in the first period to 12% in the second period (p<0.0001) (**Figure 1**).

242

243 **Potential factors associated with unfavorable outcome:**

Overall, the risk of death or admission to ICU was significantly related to the oxygen flow (p<0.001) and to lymphocyte count in a first model (i.e. lymphocyte count<1000/mm3) (HR=4.90, 95% CI [1.95 – 12.3], p=0.0007) or to high systemic inflammation in a second model (i.e. CRP \ge 100 mg/L) (HR=2.78, 95% CI [1.00 – 5.23], p=0.05). In addition, we observed a relationship between favorable outcome and use of AZI whether or not combined with HCQ, in comparison to patients without any treatment (p=0.04) **(Table 2)**.

251

252 Unfavorable outcome according to biological parameters (Kaplan Meier curves)

There was a significant interaction between treatment and CRP level (p=0.02) and at 253 the limit of statistical significance for the lymphocyte count (p=0.06) supporting a 254 subgroup analysis. In univariate analysis, patients who benefited from AZI whether or 255 not combined with HCQ with a lymphocyte count \geq 1000/mm3, were less likely to 256 have an unfavorable outcome compared to patients without any treatment (p=0.04) 257 (Fig 2.a). Concomitantly, patients who benefited from AZI whether or not combined 258 with HCQ with a CRP \geq 100 mg/L, were less likely to have an unfavorable outcome 259 compared to patients without any treatment (p=0.009) (Fig 2.b). However, these 260 results are not reproducible in patients with a lymphocyte count < 1000/mm3 (p=0.80) 261 262 and similarly in patients with a CRP level < 100 mg/L (p=0.50) (Figure S3.a, S3.b in Supplementary Data). 263

264

265 **Discussion:**

Our study highlights that unfavorable outcome (transfer to ICU and/or death) decreased over time during the management of the first wave of the epidemic and was associated with an increased realization of pulmonary CT-scan and prescription of anti-infective agents despite an increased need of oxygen therapy at admission. This suggests that medical care of COVID-19 patients improved over time in our hospital.

Because of lockdown, it looks like patients were admitted later in the second period than during the first period of the epidemic and it might explain why they required more oxygen therapy at baseline. We suggest that in case of a second wave, it could be relevant to introduce telemedicine monitoring of vital signs including pulse oximetry at home. Indeed, oxygen therapy at home, as proposed by the French

covidom platform in patients discharged from the hospital during the first wave of theepidemic was of interest [12].

In multivariate analyses, our models adjusted on the lymphocyte count or CRP, 279 showed that patients who benefited from AZI whether or not combined with HCQ 280 were 2.2 and 2.4 times less likely to have an unfavorable outcome than patients 281 without treatment (p=0.04), respectively. This finding suggests that the lymphocyte 282 count which is already known to be closely related to COVID-19 disease severity 283 [14,15] could be also a predictive factor of anti-infective therapy response. Indeed, 284 patients with lymphocyte count \geq 1000/mm³ might be patients at an early stage of 285 COVID-19, arguing for the earliest initiation of anti-infective agents, as previously 286 287 demonstrated with oseltamivir treatment in severely-ill patients with 2009 pandemic influenza A (H1N1) [16]. However, we did not study whether there was a relationship 288 between the lymphocyte count and the delay from first onset of symptoms to the 289 290 admission, because this variable is declarative and thus not reliable. Likewise, AZI whether or not combined with HCQ showed interest in hospitalized patients with a 291 high systemic inflammation (CRP level \geq 100 mg/L), known as the so called "cytokine" 292 storm". This is one argument pleading for a possible immune-modulator effect of the 293 treatment as previously described by Zhao et al. [17]. 294

Our findings are concordant with a recent study conducted in the United States by Arshad *et al.* [7] who concluded in multicenter retrospective observational study that treatment with HCQ alone and in combination with AZI was associated with reduction in COVID-19 associated mortality in hospitalized patients. Another study design issued by Lagier *et al.* [18], partly composed of ambulatory care patients, revealed a favorable outcome and a decreased virological shedding using the combination therapy of HCQ with AZI in a large sample size (n>3000), in a majority of patients

with a mild lymphocytopenia (\geq 1000/mm³). At last Mahevas *et al.* [4] observed 15/15 favorable outcome in a subgroup of patients receiving HCQ with AZI.

Interestingly, our study does focus on the potential interest of treatment with 304 azithromycin whether or not combined depending on certain biological parameters. 305 Indeed, azithromycin's potential antiviral activity is concordant with previous in vitro 306 studies regarding SARS-CoV-2 [19] or H1N1-pdm09 [20] and one clinical randomized 307 trial in in the prevention of children respiratory infections [21]. In addition a recent 308 publication emphasized the role of azithromycin against COVID-19 through the 309 CD147 receptor of stem cell [22]. Moreover, one study published in the JAMA by 310 Rosenberg *et al.* [23] highlighted a potential trend to a decreased mortality in patients 311 receiving azithromycin versus HCQ or standard of care despite being non-statistically 312 significant (p=0.14). Moreover, authors discussed that the rapidity with which patients 313 entered the ICU (within 48 hours) might have underestimated the treatment efficacy. 314 315 Also, as azithromycin is commonly prescribed for bronchitis and authorized in ambulatory care, a study conducted among general practitioners could be relevant to 316 evaluate early indication of this single therapy for the treatment of COVID-19 in 317 fragile outpatients. 318

In addition, our experience does not report any serious side effect of this combination therapy as long as we take the necessary caution and perform follow-up ECG using a conventional dose of HCQ as proposed by Borba *et al.* [24].

Our study has several limitations. The first limitation is the single center nature of the study, describing the experience of a unique center whose results might not be generalizable. However, it was carried out in a hospital specialized for decades in the treatment of infectious diseases, ICU and rehabilitation. Since the beginning of the COVID-19 epidemic, an entire building has been entirely dedicated to admitting only

327 COVID-19 positive patients. During the peak of the epidemic, we had a maximum 328 capacity of 85 beds in medicine ward and 32 beds in ICU.

Furthermore, we observed a better favorable outcome over time related to an 329 increased number of pulmonary CT-scan performed (not recommended at the 330 beginning of the epidemic in our hospital) and therefore a more relevant prescription 331 of anti-infective agents. Nevertheless, we cannot exclude that other confounding 332 factors might have played a role, as we were facing an unpredictable epidemic, which 333 urged to update constantly guidelines about ICU admission, notably recommending 334 to keep patients longer in medicine wards with high oxygen flow (>6L/min) during the 335 second period of the epidemic. Nevertheless, delay between admission and transfer 336 in ICU were similar between the 2 periods of time which minimizes this confounding 337 factor. 338

Moreover, considering inherent limitation of a descriptive study with a limited sample 339 size (n=132), we could not infer causality in the association between the use of 340 AZI±HCQ and the ameliorated prognosis in COVID-19 patients. Besides, we also 341 noted that some unforeseen confounders (e.g., pre-hospital medication and delay to 342 admission) may still potentially alter the magnitude of azithromycin effects on the 343 outcome of COVID-19 pneumonia. Also, choices in anti-infective agents have differed 344 between the first and second period, notably because prior to March 25th, HCQ was 345 not authorized by the French minister of Health and explained partly the common use 346 of lopinavir-ritonavir at this period. 347

Finally, we decided to choose a multivariate model rather than a propensity score because the aim of this study was not to evaluate the effect of AZI±HCQ on the prognosis but to evaluate all factors which could have impacted on medical care.

In conclusion, findings from this study showed that rate of admission in ICU decreased from 43% during the first period (from March 5th to March 19th) to 12% during the second period (from March 20th to April 25th).

Numerous factors might be involved in the improvement of care, including the 354 implementation of routine pulmonary CT-scan, better management of oxygen therapy 355 in medicine ward and possibly anti-infective agents. Indeed, our study suggests that 356 AZI±HCQ might have impacted COVID-19 outcome in a subpopulation of patients 357 (lymphocyte count \geq 1000/mm3 or CRP \geq 100 mg/L), raising the guestion of optimal 358 timing of treatment interventions. A larger and randomized controlled study is 359 necessary to explore the profiles of patients responding to this therapeutic and 360 confirm the potential interest of biological parameters for treatment initiation. 361

362

363 **Contributors' Statement:**

BD, PDT and CP conceptualized and designed the study, carried out the initial analyses, coordinated and supervised data collection, drafted the initial manuscript, and reviewed the manuscript.

BD, FB, PDT, TL designed the data collection instruments, collected data and reviewed and revised the manuscript. VP, DA, PM, AL participated to patients enrollment.

370 GB and IV were in charge of the statistical analyses and contributed to the final 371 version of the manuscript.

All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

375

376 Acknowledgments:

- 377 Authors would like to thank Pr Xavier Paoletti for his proofreading of the manuscript
- and his particular attention to the statistical analyses.
- 379

380 **Declarations**

- **Funding**: The authors have no financial relationships relevant to this article to disclose.
- 383 Competing Interests: BD has received consulting fees or travel grants from ViiV
- Healthcare and Gilead Sc. PdT has received consulting fees or travel grants from
- ViiV Healthcare, M.S.D and Gilead Sc. The remaining authors have no specific
- 386 conflict of interest.
- 387 Ethical Approval: Not required
- 388 Randomized Controlled Trial : NCT04453501
- 389 List of Collaborators
- 390 **COVID-19 RPC Team*
- 391 Department of Intensive Care
- 392 Djillali Annane, MD, PhD (1,2,5)
- 393 Xavier Ambrosi, MD (4)
- 394 Suzanne Amthor, MD (1)
- 395 Rania Bounab, MD (1,2)
- 396 Ryme Chentouh, MD (1)
- 397 Bernard Clair, MD (1)
- 398 Abdallah Fayssoil, MD (1,2,5)
- 399 Diane Friedman, MD (1)
- 400 Nicholas Heming, MD, PhD (1,2,5)401 Virginie Maxime, MD, (1)
- 401 Virginie Waxine, WD, (1) 402 Pierre Moine, MD, PhD (1,2,5)
- 403 Myriam Niel Duriez, MD (1)
- 404 David Orlikowski, MD, PhD (1,2,5,8)
- 405 Francesca Santi, MD (1,2)
- 406
- 407 <u>Pharmacy</u>
- 408 Frédérique Bouchand, PharmD (1)
- 409 Muriel Farcy-Afif, PharmD (1)

410 Hugues Michelon, PharmD, MSc (1) Maryvonne Villart, PharmD (1) 411 412 413 **Research Staff** Isabelle Bossard (8) 414 415 Tiphaine Barbarin Nicolier (1) Stanislas Grassin Delyle, MCUPH (2,3,5) 416 Elodie Lamy (2,5)417 Camille Roquencourt, MD (5) 418 Gabriel Saffroy (2) 419 Etienne Thevenot (5) 420 421 422 Department of Intensive Care Interns 423 Baptiste Abbar (1) 424 Steven Bennington (1) Juliah Dray (1) 425 Pierre Gay (1) 426 427 Elias Kochbati (1) Majistor Luxman (1) 428 Myriam Moucachen (1) 429 Alice Pascault (1) 430 Juan Tamayo (1) 431 Justine Zini (1) 432 433 Department of Anesthesia, Perioperative Care, and Pain 434 435 Marie Boutros, MD (1) Anne Lyse Bron, MD (11) 436 437 Denys Coester, MD (12) Etiennette Defouchecour, MD (11) 438 Brigitte Dosne Blachier, MD (11) 439 440 Léa Guichard, MD (1) Damien Hamon Pietrin, MD, PhD (1) 441 Hakim Khiter, MD (1) 442 443 Valéria Martinez, MD, PhD (1,2,6) Simone Meuleye, MD (1) 444 Suzanne Reysz, MD (1) 445 446 Sebastien Schitter, MD (1) Chawki Trabelsi, MD (1) 447 448 449 Pediatric Critical Care Unit Helge Amthor, MD, PhD (1,2,7) 450 Jean Bergounioux MD (1,2,5) 451 Maud Guillon, MD (1) 452 Amal Omar, MD (1) 453 454 Laboratory of Physiology 455

- 456 Frédéric Lofaso, MD, PhD (1,2,7,10)
- 457 Helene Prigent, MD, PhD (1,2,7,10)
- 458
- 459 Department of Rehabilitation and Physical Medicine
- 460 Djamel Bensmail, MD, PhD (1,2,7,10)
- 461 Pierre Denys, MD, PhD (1,2,7,10)
- 462 Charles Joussain, MD, PhD (1)
- 463 Lauren Kagane, MD (1)
- 464 Thibaut Lansaman, MD (1)
- 465 Hélène Le Liepvre, MD (1)
- 466 Antoine Leotard, MD, MS (1)
- 467 Jonathan Levy, MD, MS (1,2,7,10)
- 468 Claire Malot, MD (1)
- 469 Julie Paquereau, MD (1)
- 470 Celia Rech, MD (1)
- 471
- 472 Department of Rehabilitation Interns
- 473 Florence Angioni (1)
- 474 Elsa Chkron (1)
- 475 Céline Karabulut (1)
- 476 Jérôme Lemoine (1)
- 477 Noémie Trystram (1)
- 478 Julien Vibert (1)
- 479
- 480 Department of Infectious Diseases
- 481 Pascal Crenn, MD, PhD (1,2,7)
- 482 Benjamin Davido, MD, MS (1)
- 483 Stéphanie Landowski, MD (1)
- 484 Christian Perronne, MD, PhD (1,2)
- 485 Véronique Perronne, MD (1)
- 486 Pierre de Truchis, MD, MS (1)
- 487
- 488 Department of Infectious Diseases Interns
- 489 Marc Hobeika (1)
- 490 Louis Jacob (1)
- 491 Nicolas Kiavue (1)
- 492 Aymeric Lanore (1)
- 493 Aurélie Le Gal (1)
- 494 Julia Nguyen Van Thang (1)
- 495
- 496 Department of Microbiology and Innovative Biomarkers Platform
- 497 Coralie Favier (1)
- 498 Jean Louis Gaillard, MD, PhD (1,2,5)
- 499 Elyanne Gault, MD, PhD (1,2,5)
- 500 Jean-Louis Herrmann, PharmD, PhD (1,2,5)
- 501 Christine Lawrence, PharmD (1)

Virginie Lebidois, PharmD (1) 502 Latifa Noussair, MD (1) 503 504 Martin Rottman, MD, PhD (1,2,5) Anne-Laure Roux, PharmD, PhD (1,2,5) 505 Sophie Tocqueville (1) 506 507 Marie-Anne Welti, MD, PhD (1,2,5) And the nonmedical staff of the Department 508 509 510 Department of Laboratory Medicine and Pharmacology Jean Claude Alvarez, MD, PhD (1,2,5) 511 Mehdi Djebrani, PharmD (1) 512 Pierre-Alexandre Emmanuelli (1) 513 Firas Jabbour, PharmD (1) 514 Lotfi Lahjomri, MD (1) 515 Mathilde Parent, MD (1) 516 And the nonmedical staff of the Department 517 518 519 Department of Radiology Amine Ammar, MD (1) 520 Najete Berradja, MD (1) 521 Robert-Yves Carlier, MD, MS (1,2,7,14) 522 Annaelle Chetrit, MD (1,2) 523 Caroline Diffre, MD (1,2)524 Myriam Edjlali, MD, PhD (1,15) 525 526 Zaki El Baz, MD (1,14) Adrien Felter, MD (1) 527 Catherine Girardot, MD (1,13) 528 529 Ahmed Mekki, MD, MS (1,2) Dominique Mompoint, MD (1) 530 Dominique Safa, MD (1) 531 532 Tristan Thiry, MD (1) 533 534 Department of Radiology Interns 535 Margot Armani (1) Olivier de Barry (1) 536 Antoine Kirchner (1) 537 538 Jeffery Zhou (1) 539 540 Department of Forensic Medicine Geoffroy Lorin de La Grandmaison MD, PhD (1) 541 542 543 Department of Forensic Medicine Intern 544 Kevin Mahe (1) 545

546 Affiliations

547	1.	Hôpital Raymond Poincaré, GHU APHP, Université Paris Saclay, Garches, France
548 549	2.	Faculté Simone Veil Santé, Université Versailles Saint Quentin en Yvelines, Université Paris Saclay, Montigny-le-Bretonneux, France
550	3.	Hôpital Foch, Suresnes, France
551	4.	Centre Hospitalier Universitaire de Nantes, Nantes, France
552 553	5.	Université de Versailles Saint-Quentin-en-Yvelines/INSERM, Laboratory of Infection & Inflammation–U-1173, Montigny-le-Bretonneux, France
554 555	6.	Université de Versailles Saint-Quentin-en-Yvelines/INSERM, Centre d'Evaluation et de Traitement de la Douleur–U-987, Boulogne-Billancourt, France
556 557	7.	Université de Versailles Saint-Quentin-en-Yvelines/INSERM, Handicap Neuromusculaire–U- 1179, Montigny-le-Bretonneux, France
558	8.	Centre d'Investigation Clinique, Garches, France
559	9.	Commissariat à l'Energie Atomique, CEA Paris Saclay, Gif-sur-Yvette, France
560	10.	Fondation Garches, Garches, France
561	11.	Clinique Jouvenet, Ramsay Santé, Paris, France
562	12.	Clinique de la Muette, Ramsay Santé, Paris, France
563	13.	Polyclinique Mantaise, Mantes-La-Jolie, France
564	14.	Centre Hospitalier Intercommunal Poissy/Saint-Germain, GHT Yvelines Nord, Poissy, France
565 566	15.	IMA-BRAIN/INSERM–UMR-1266, DHU-Neurovasc, Centre Hospitalier Sainte-Anne, Paris, France
567		

568 **References:**

- 569 [1] Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Sevestre J, et al.
- 570 Clinical and microbiological effect of a combination of hydroxychloroquine and
- azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot
- observational study. Travel Med Infect Dis 2020:101663.
- 573 doi:10.1016/j.tmaid.2020.101663.
- 574 [2] Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al.
- 575 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of
- an open-label non-randomized clinical trial. Int J Antimicrob Agents
- 577 2020:105949. doi:10.1016/j.ijantimicag.2020.105949.
- 578 [3] Million M, Lagier J-C, Gautret P, Colson P, Fournier P-E, Amrane S, et al. Early

- treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A
 retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis
 2020:101738. doi:10.1016/j.tmaid.2020.101738.
- 582 [4] Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al.
- 583 Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia
- who require oxygen: observational comparative study using routine care data.
- 585 BMJ 2020;369:m1844. doi:10.1136/bmj.m1844.
- 586 [5] Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational
- 587 Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J
- 588 Med 2020:NEJMoa2012410. doi:10.1056/NEJMoa2012410.
- [6] Russell CD, Millar JE, Baillie JK. Clinical evidence does not support
 corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395:473–5.
 doi:10.1016/S0140-6736(20)30317-2.
- 592 [7] Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, et al.
- 593 Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients 594 Hospitalized with COVID-19. Int J Infect Dis 2020;0.
- 595 doi:10.1016/j.ijid.2020.06.099.
- 596 [8] Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-
- 597 Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med
- 598 2020:NEJMoa2001282. doi:10.1056/NEJMoa2001282.
- [9] Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with
 severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre
 trial. Lancet 2020;395:1569–78. doi:10.1016/S0140-6736(20)31022-9.

602	[10]	Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al.
603		Remdesivir for the Treatment of Covid-19 — Preliminary Report. N Engl J Med
604		2020. doi:10.1056/neimoa2007764.

- [11] Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
- prognostic comorbidity in longitudinal studies: development and validation. J
 Chronic Dis 1987;40:373–83.
- 608 [12] Group TC-A. Assistance Publique–Hôpitaux de Paris' response to the COVID609 19 pandemic. Lancet 2020. doi:10.1016/S0140-6736(20)31210-1.
- 610 [13] SRLF-SFAR-SFMU-GFRUP-SPILF-SPLF. Recommandations d'experts portant

sur la prise en charge en réanimation des patients en période d'épidémie à

612 SARS-CoV2 2020:29. https://www.srlf.org/wp-content/uploads/2020/03/RFE-

613 COVID_V3_FINAL-1.pdf.

- [14] ET, IN-S, IE, EK, TNS, MP, et al. Hematological Findings and
- 615 Complications of COVID-19. Am J Hematol 2020. doi:10.1002/AJH.25829.
- [15] Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang Y-Q, et al. Lymphopenia
- 617 predicts disease severity of COVID-19: a descriptive and predictive study.
- 618 Signal Transduct Target Ther 2020;5:33. doi:10.1038/s41392-020-0148-4.
- [16] Kumar A. Early versus late oseltamivir treatment in severely ill patients with
- 2009 pandemic influenza A (H1N1): speed is life n.d. doi:10.1093/jac/dkr090.
- [17] Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: Role of
- chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents
 2020:105982. doi:10.1016/j.ijantimicag.2020.105982.

[18] Lagier J-C, Million M, Gautret P, Colson P, Cortaredona S, Giraud-Gatineau A,

et al. Outcomes of 3,737 COVID-19 patients treated with

626 hydroxychloroquine/azithromycin and other regimens in Marseille, France: A

retrospective analysis. Travel Med Infect Dis 2020:101791.

- 628 doi:10.1016/J.TMAID.2020.101791.
- [19] Touret F, Gilles M, Barral K, Nougairède A, Decroly E, Lamballerie X de, et al.
- In vitro screening of a FDA approved chemical library reveals potential
- inhibitors of SARS-CoV-2 replication. BioRxiv 2020:2020.04.03.023846.
- 632 doi:10.1101/2020.04.03.023846.
- [20] DH T, R S, T H, S S, Y N, A S, et al. Azithromycin, a 15-membered Macrolide
- Antibiotic, Inhibits Influenza A(H1N1)pdm09 Virus Infection by Interfering With
 Virus Internalization Process. J Antibiot (Tokyo) 2019;72. doi:10.1038/S41429019-0204-X.
- [21] LB B, TW G, DT M, S B, A B, AM F, et al. Early Administration of Azithromycin
 and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool
 Children With a History of Such Illnesses: A Randomized Clinical Trial. JAMA
- 640 2015;314. doi:10.1001/JAMA.2015.13896.
- [22] Ulrich H, Pillat MM. CD147 as a Target for COVID-19 Treatment: Suggested
 Effects of Azithromycin and Stem Cell Engagement 2015. doi:10.1007/s12015020-09976-7.
- [23] Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et
- al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-
- Hospital Mortality in Patients With COVID-19 in New York State. JAMA
- 647 2020;323:2493. doi:10.1001/jama.2020.8630.

- 648 [24] Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al.
- 649 Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive
- Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome
- 651 Coronavirus 2 (SARS-CoV-2) Infection. JAMA Netw Open 2020;3:e208857.
- 652 doi:10.1001/jamanetworkopen.2020.8857.




Figure 1: Evolution of medical care for COVID-19 patients from March 5th to April 25th

Figure 2.a. Kaplan-Meier survival curve for patients with an unfavorable outcome in function of treatment according to lymphocyte count \geq 1000/mm3 (Log-Rank, *p* = 0.04).





Figure 2.b. Kaplan-Meier survival curve for patients with an unfavorable outcome in function of treatment according to CRP \ge 100 mg/L (Log-Rank, *p* = 0.009).



Characteristics at baseline	In first period †	In second period ‡	p value	
	N= 40	N= 92		
Age (year) — mean ± SD	62.17 ± 15.24	57.59 ± 16.64	0.13	
Sex (M) — no. (%)	26 (58)	59 (64)	0.99	
Obesity — no. (%)	2 (4)	13 (14)	0.22	
Smoking (yes) — no. (%)	13 (29)	16 (17)	0.09	
CCI* — no. (%)				
0	4 (10)	20 (22)		
1-2	14 (35)	33 (36)	0.20	
3-4	11 (28)	20 (22)	0.38	
≥5	11 (28)	19 (21)		
Pulmonary CT scan — no. (%)	20 (50)	83 (90)	<0.0001	
Normal	2 (10)	5 (6)		
Limited	6 (30)	11 (13)		
Mild	0 (0)	24 (29)	0.46	
Moderate	9 (45)	32 (39)		
Severe	3 (15)	11 (13)		
Lymphocyte count < 1000/mm3 — no. (%)	17 (42)	54 (59)	0.13	
PMN count >8000/mm3	5 (13)	9 (10)	0.64	
$CRP mg/L - mean \pm SD$	84.59 ± 70.31	83.70 ± 71.86	0.95	
Oxygen (yes) — no. (%)	21 (53)	74 (80)	0.001	
≤2L/min	10 (48)	38 (51)		
2 – 5 L/min	10 (48)	27 (36)	0.55	
>5 L/min	1 (5)	9 (12)		
Treatment strategies — no. (%)				
No treatment	30 (75)	22 (24)		
AZI ± HCQ	10 (25)	70 (76)	<0.0001	

Table 1: Baseline characteristics of patients with COVID-19 according to periods of hospitalization

† In first period is define between 03/05 to 03/19; ‡In second period is define between 03/20 to 04/25; AZI, Azithromycin; HCQ, Hydroxychloroquine; N, number; %, percent; SD, standard deviation; M, men; Obesity with body mass index ≥ 30 kg/m²; *CCI, Charlson Comorbidity Index; PMN, polymorphonuclear leukocyte; CRP, c-reactive protein; CT : computerized tomography; pulmonary CT scan category normal [0%], limited <10%, mild 10% – 25%, Moderate 25% – 50%, Severe >50%; A Student test (equal variance) or a Welche-Satterthwaite t test (unqual variance) was used to analyze the quantitative variables, a Mantel-Haenszel Chi-Square test was used to analyze the qualitative variables and the exact test of Fisher was used when the sample sizes were small (<5). Test significant (p<0.05)

Variables	n/N	Univariate model		Multivariate model 1			Multivariate model 2			
		HR [IC95%]	p val	ue	HR [IC95%]	<i>p</i> value	•	HR [IC95%]	<i>p</i> val	lue
				Adjusted on ICC, obesity, O2, lymphocyte count and treatments		ocyte	Adjusted on ICC, obesity,O2 CRP and treatments			
Characteristics at baseline										
Age (years)	132/132	1.02 [1.00 – 1.05]	0.07		-	-		-	-	
Sex (M)	85/132	0.86 [0.40 – 1.85]	0.71		-	-		-	-	
Obesity (yes)	15/132	0.27 [0.04 – 1.98]	0.20		0.47 [0.06- 3.63]	0.47		0.44 [0.06 - 3.45]	0.43	
Smoking (yes)	29/132	1.00 [0.41 - 2.48]	0.99		-	-		-	-	
CCI*										
0	24/132	1*	-		1*	-		1	-	
1-2	47/132	0.88 [0.26 - 3.00]	0.83		1.05 [0.29 – 3.87]	0.47		1.10 [0.31 – 3.92]	0.89	
3-4	31/132	1.88 [0.58 – 6.12]	0.29	0.39	1.30 [0.37 – 4.54]	0.68	0.97	1.74 [0.52 – 5.81]	0.37	0.73
≥5	30/132	1.63 [0.49 – 5.43]	0.42		1.10 [0.32 – 3.75]	0.87		1.08 [0.32 – 3.71]	0.90	
PMN count≥8000/mm3	14/132	1.42 [0.49 – 4.10]	0.52		-	-		-	-	
Lymphocyte count < 1000/mm3	71/132	4.91 [1.99 – 12.1]	0.0006		4.90 [1.95 – 12.3]	0.0007		-	-	
$CRP \ge 100 \text{ mg/L}$	85/132	2.86 [1.35 - 6.05]	0.006		-	-		2.78 [1.00 – 5.23]	0.05	
Treatment strategies										
Oxygen (L/min)		1.20 [1.10 - 1.31]	<0.0001		1.25 [1.13 – 1.38]	<0.0001		1.20 [1.08 - 1.32]	0.0005	
No treatment and	52/132	1*	-		1*	-		1*	-	
AZI ± HCQ	80/132	0.63 [0.30 – 1.23]	0.23		0.45 [0.21 – 0.97]	0.04		0.42 [0.18 - 0.95]	0.04	

Table 2: Potential factors associated to unfavorable outcome: Cox model regression

n/N number/total; 1* indicates the reference category; HR, Hazard ratio; CI, confidence interval; NS, not significant (p> 0.05); PMN, polymorphonuclear; *CCI, The Charlson Comorbidity Index; CRP, C Reactive protein; AZI, Azithromycin; HCQ, Hydroxychloroquine; No treatment defined as patients who have had no treatment or lopinavir-ritonavir; Multivariate Cox model regression was used to identify the potential factors associated with unfavorable outcome (ICU admission or death after ICU), adjusted on CCI (including age), obesity, oxygen and treatment strategies groups according to CRP.